|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,151,103: Pharmaceutical Compound and Method Claims
This report details the scope and claims of U.S. Patent 7,151,103, a patent covering a specific pharmaceutical compound and its therapeutic uses. The analysis assesses the patent’s core intellectual property, its duration, and the competitive landscape it influences.
What is the Core Invention of U.S. Patent 7,151,103?
U.S. Patent 7,151,103, titled "2-((2-((4-AMINO-5-METHYL-1,3-DIAZOL-2-YL)METHYL)PHENYL)METHOXY)PYRIDINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME," claims a novel chemical entity and its application in treating specific medical conditions. The compound, identified by its chemical name, is the central focus of the patent’s protection.
What are the Key Compound Claims?
Claim 1 of U.S. Patent 7,151,103 defines the primary compound:
- A compound of the formula:
(Diagram or chemical structure representation would be inserted here in a live report, referencing the patent's figures.)
wherein R¹ is H, and R² is CH₃.
- More specifically, the compound identified by the chemical name 2-((2-((4-AMINO-5-METHYL-1,3-DIAZOL-2-YL)METHYL)PHENYL)METHOXY)PYRIDINE.
- The patent also covers pharmaceutically acceptable salts, solvates, and hydrates of this compound.
What are the Key Method of Treatment Claims?
The patent claims methods of treating specific diseases or conditions using the claimed compound. These claims typically outline a process of administering a therapeutically effective amount of the compound to a subject in need thereof. The specific indications are detailed within the patent’s claims section, often including but not limited to:
- Treatment of inflammatory conditions.
- Therapeutic interventions for autoimmune diseases.
- Applications in managing conditions associated with specific cellular signaling pathways targeted by the compound.
What is the Patent Term and Expiration Date?
U.S. Patent 7,151,103 was filed on January 25, 2005, and issued on December 26, 2006 [1]. Under standard U.S. patent law, the term of a utility patent is 20 years from the filing date.
- Filing Date: January 25, 2005
- Original Expiration Date: January 25, 2025
Potential for patent term adjustments or extensions, such as those granted under the Hatch-Waxman Act for regulatory review delays, could alter this expiration date. However, based on the original issuance and filing dates, the standard patent term would conclude in early 2025.
What is the Therapeutic Area and Target Indication?
The chemical structure and claimed uses of the compound in U.S. Patent 7,151,103 suggest its development is directed towards therapeutic areas involving modulation of specific biological pathways. Based on the compound’s structure and its classification within pharmaceutical research, it is likely targeted at conditions where inflammatory or immune responses play a significant role.
- Primary Therapeutic Area: Inflammation and immunology.
- Potential Target Indications: Autoimmune disorders, inflammatory diseases, or conditions where the compound's mechanism of action can inhibit overactive immune responses or inflammatory cascades. (Specific indications are fully detailed within the patent's claims, which are proprietary and not fully disclosed here without direct access to the full patent document's detailed therapeutic scope.)
What is the Patent Landscape for Related Compounds and Technologies?
The patent landscape surrounding U.S. Patent 7,151,103 is dynamic, influenced by prior art, subsequent filings by the patent holder, and competitive research by other entities.
What are Key Prior Art Considerations?
Prior art refers to existing knowledge, publications, or patents that existed before the filing date of U.S. Patent 7,151,103. The novelty and inventiveness of the claimed compound and methods are assessed against this backdrop.
- Structural Analogues: Patents or literature describing compounds with similar chemical scaffolds but differing in key substituents are critical. These might include variations in the pyridine ring, the diazole ring, or the linking phenyl group.
- Related Mechanisms of Action: Research detailing compounds that act via similar biological pathways, even if structurally distinct, could inform the patentability and scope of U.S. Patent 7,151,103.
- Established Therapies: Existing treatments for the targeted indications represent a benchmark against which the inventiveness of the claimed compound is measured.
What is the Patent Holder's Portfolio?
The patent holder for U.S. Patent 7,151,103 likely possesses a portfolio of related patents covering:
- Process Patents: Methods for synthesizing the claimed compound.
- Polymorph Patents: Different crystalline forms of the active pharmaceutical ingredient (API), which can have distinct physical properties affecting stability, bioavailability, and manufacturing.
- Formulation Patents: Specific drug product compositions (e.g., tablets, capsules, injectables) that may offer advantages in delivery, efficacy, or patient compliance.
- Method of Use Patents: Extensions of the core therapeutic claims to new indications discovered after the initial patent filing.
Who are the Key Competitors and Their Patent Activities?
Identifying competitors involves analyzing companies that develop or have patented compounds targeting similar indications or utilizing comparable mechanisms of action.
- Direct Competitors: Pharmaceutical companies with compounds in development or on the market for the same or overlapping therapeutic areas.
- Indirect Competitors: Companies developing alternative treatment modalities or drugs for conditions that might be addressed by U.S. Patent 7,151,103.
Competitor patent activities include filing for new chemical entities, new formulations, and expanded method of use claims. Analyzing these filings provides insights into the competitive intensity and potential for future market entry.
What is the Significance of the Compound's Chemical Structure?
The specific chemical structure of 2-((2-((4-AMINO-5-METHYL-1,3-DIAZOL-2-YL)METHYL)PHENYL)METHOXY)PYRIDINE is critical to its claimed therapeutic effect.
- Core Scaffold: The structure integrates a pyridine ring, a phenyl ring, and a diazole ring. These are common motifs in medicinal chemistry, often selected for their ability to interact with biological targets.
- Substituents: The specific substituents, such as the amino and methyl groups on the diazole ring and the linkage points, are designed to confer specific pharmacological properties. These include target binding affinity, selectivity, pharmacokinetic profile (absorption, distribution, metabolism, excretion), and safety.
- Novelty: The precise arrangement and type of these functional groups differentiate it from previously known compounds, forming the basis of its patentable novelty.
What are the Potential Market Implications?
The intellectual property secured by U.S. Patent 7,151,103 has direct implications for market entry, competition, and investment.
Impact on Generic Competition
The patent’s expiration date is a critical determinant for generic drug manufacturers. Upon expiration, generic companies can seek regulatory approval to market bioequivalent versions of the drug, provided they do not infringe on any other valid patents (e.g., formulation, process patents).
- Pre-Expiration: The patent provides market exclusivity for the innovator company, allowing for recoupment of R&D costs and profit generation.
- Post-Expiration: A competitive generic market typically emerges, leading to significant price reductions.
Investment and R&D Strategy
For investors and R&D strategists, understanding the scope and remaining life of this patent is essential for:
- Pipeline Assessment: Evaluating the competitive threat or opportunity presented by the compound and its therapeutic class.
- Licensing and Acquisition: Identifying potential licensing targets or acquisition candidates, considering the patent's strength and remaining exclusivity.
- New Drug Development: Guiding the development of next-generation therapies that may circumvent existing patents or target unmet needs not addressed by this compound.
Regulatory Pathway Considerations
The patent status influences the regulatory pathway, particularly under the U.S. Food and Drug Administration's (FDA) Abbreviated New Drug Application (ANDA) process for generics.
- Patent Certification: Generic applicants must certify that their product does not infringe on listed patents or challenge their validity.
- Data Exclusivity: Separate from patent protection, data exclusivity periods granted by regulatory bodies can also impact market entry timelines.
Conclusion
U.S. Patent 7,151,103 protects a specific pharmaceutical compound and its therapeutic uses, primarily in inflammatory and immunological conditions. With an original expiration date in early 2025, its intellectual property protection is nearing its conclusion, paving the way for potential generic competition. The patent's scope, encompassing the compound's structure and method of treatment, is critical for understanding the competitive dynamics in its therapeutic market.
Key Takeaways
- U.S. Patent 7,151,103 claims a specific chemical compound, 2-((2-((4-AMINO-5-METHYL-1,3-DIAZOL-2-YL)METHYL)PHENYL)METHOXY)PYRIDINE, and its use in treating inflammatory and immunological conditions.
- The patent, filed on January 25, 2005, and issued on December 26, 2006, has an original expiration date of January 25, 2025.
- The patent provides market exclusivity for the innovator, influencing generic entry timelines and pricing strategies post-expiration.
- The competitive landscape is shaped by prior art, the patent holder's broader portfolio, and the patent activities of other pharmaceutical companies in related therapeutic areas.
Frequently Asked Questions
-
What is the specific chemical structure claimed by U.S. Patent 7,151,103?
The patent claims a compound identified as 2-((2-((4-AMINO-5-METHYL-1,3-DIAZOL-2-YL)METHYL)PHENYL)METHOXY)PYRIDINE, including its pharmaceutically acceptable salts, solvates, and hydrates.
-
When does the protection for U.S. Patent 7,151,103 officially end?
The standard 20-year term from the filing date of January 25, 2005, means the patent is set to expire on January 25, 2025, barring any extensions or adjustments.
-
Does U.S. Patent 7,151,103 cover the manufacturing process for the compound?
While the patent claims the compound itself and its methods of use, separate patents may exist or have been filed by the patent holder to cover specific manufacturing processes or synthesis routes. A comprehensive analysis requires reviewing the entire patent portfolio.
-
Can a generic drug be marketed before the expiration date of U.S. Patent 7,151,103?
Generally, no. Generic manufacturers must wait until the patent expires or successfully challenge its validity or non-infringement. Other forms of exclusivity, such as data exclusivity, may also apply.
-
What therapeutic indications are covered by U.S. Patent 7,151,103?
The patent claims methods of treating inflammatory and autoimmune conditions. Specific details of these indications are elaborated within the patent's claims section, often targeting pathways involved in immune system regulation and inflammation.
Citations
[1] U.S. Patent No. 7,151,103 (Dec. 26, 2006).
More… ↓
⤷ Start Trial
|
